Phase 2 data demonstrated 17.5-month median overall survival in advanced, chemo-refractory patients with microsatellite stable colorectal cancer (MSS-CRC) Company closed $22M financing to support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback